Advertisement

Medical Management of Obesity

  • Robert C. AndrewsEmail author

Abstract

The term obesity implies an excess of adipose tissue and excess adiposity is a health risk. Patients with obesity are at increased risk of many medical and psychiatric diseases, they have reduced life expectancy, and are also subjected to unwanted social, psychological, and physical disadvantages. As a result of these factors the cost to individuals and society due to obesity is huge. For these reasons prevention and treatment of obesity is now widely recognised as a chief priority.

The aim of treatment is to reduce morbidity and mortality while improving psychological well-being and social function. Interventions are costly and time consuming and thus should be targeted at patients who at the most risk (BMI >30 or BMI >27 + serious co-morbidities of obesity) and motivated.

Overeating and decreased activity are the fundamental problems underlying the development of obesity, thus any therapy aimed at helping the obese patient must have a dietary and physical activity (PA) component. Initially patients should be encouraged to increase their PA to 60 min 5 days per week and reduce their total energy intake by 500–1000 kcal/day. The aim is to lose 5–10 % of weight at a rate of 0.5–1 kg/week. If after 6 months significant weight-loss has not been achieved then obesity drugs can be added.

Encouraging patients to loss and maintain weight loss can be difficult. Using behavioural techniques and helping patients to identify their barriers to change and providing them with tools to overcome this will improve adherence and aid with weight loss and maintenance of this.

This chapter covers the clinical assessment of obesity, what treatment options are available and how to use these.

Keywords

Activity Diet Barriers Behavioural therapy Obesity drugs NES BED 

References

  1. 1.
    National Institute for health and Clinical Excellence (NICE) guidelines (CG189). Obesity: identification, assessment and management of overweight and obesity in children, young people and adults. https://www.nice.org.uk/guidance/cg189.
  2. 2.
    Vallis M, Piccinini-Vallis H, Sharma AM, Freedhoff Y. Clinical review: modified 5 As: minimal intervention for obesity counseling in primary care. Can Fam Physician. 2013;59(1):27–31.PubMedCentralPubMedGoogle Scholar
  3. 3.
    Peeters A, Barendregt JJ, Willekens F, Mackenbach JP, Al Mamun A, Bonneux L; NEDCOM, the Netherlands Epidemiology and Demography Compression of Morbidity Research Group. Obesity in adulthood and its consequences for life expectancy: a life-table analysis. Ann Intern Med. 2003;138(1):24–32.Google Scholar
  4. 4.
    Lean ME, Han TS, Morrison CE. Waist circumference as a measure for indicating need for weight management. BMJ. 1995;311(6998):158–61.PubMedCentralCrossRefPubMedGoogle Scholar
  5. 5.
    Mauro M, Taylor V, Wharton S, Sharma AM. Barriers to obesity treatment. Eur J Intern Med. 2008;19(3):173–80.CrossRefPubMedGoogle Scholar
  6. 6.
    Kramer RE, Daniels SR. Evaluation of a child for secondary causes of obesity and comorbidities. Nat Rev Endocrinol. 2009;5(4):227–32.CrossRefPubMedGoogle Scholar
  7. 7.
    American Psychiatric Association. Diagnostic and statistical manual of mental disorders. 4th ed. Washington, DC: American Psychiatric Association; 1994.Google Scholar
  8. 8.
    Spitzer RL, Yanovski S, Wadden T, Wing R, Marcus MD, Stunkard A, Devlin M, Mitchell J, Hasin D, Horne RL. Binge eating disorder: its further validation in a multisite study. Int J Eat Disord. 1993;13(2):137–53.PubMedGoogle Scholar
  9. 9.
    Rand CS, Macgregor AM, Stunkard AJ. The night eating syndrome in the general population and among postoperative obesity surgery patients. Int J Eat Disord. 1997;22(1):65–9.CrossRefPubMedGoogle Scholar
  10. 10.
    Prochaska JO, DiClemente CC, Norcross JC. In search of how people change: applications to addictive behaviours. Am Psychol. 1992;47:1102–14.CrossRefPubMedGoogle Scholar
  11. 11.
    Grilo CM, Masheb RM, Wilson GT. Efficacy of behavioural therapy and fluoxetine for the treatment of binge eating disorder; a randomised double-blind placebo controlled comparison. Biol Psychiatry. 2005;57:301–9.CrossRefPubMedGoogle Scholar
  12. 12.
    Golay A, Laurent-Jaccard A, Habicht F, Gachoud JP, Chabloz M, Kammer A, Schutz Y. Effect of orlistat in obese patients with binge eating disorder. Obes Res. 2005;13(10):1701–8.CrossRefPubMedGoogle Scholar
  13. 13.
    National Institute for Clinical Excellence. National Institute for Clinical Excellence GC9 eating disorders: NICE guideline. 2004. Http://www.nice.org.uk/CG009NICEguideline.
  14. 14.
    Wilson GT, Fairburn CG. The treatment of binge eating disorder. Eur Eat Disord Rev. 2000;8:351–4.CrossRefGoogle Scholar
  15. 15.
    Wilfley DE, Welch RR, Stein RI, Spurrell EB, Cohen LR, Saelens BE, Dounchis JZ, Frank MA, Wiseman CV, Matt GE. A randomized comparison of group cognitive-behavioral therapy and group interpersonal psychotherapy for the treatment of overweight individuals with binge-eating disorder. Arch Gen Psychiatry. 2002;59(8):713–21.CrossRefPubMedGoogle Scholar
  16. 16.
    Carter WP, Hudson JI, Lalonde JK, Pindyck L, McElroy SL, Pope Jr HG. Pharmacologic treatment of binge eating disorder. Int J Eat Disord. 2003;34(Suppl):S74–88.CrossRefPubMedGoogle Scholar
  17. 17.
    Appolinario JC, Bacaltchuk J, Sichieri R, Claudino AM, Godoy-Matos A, Morgan C, Zanella MT, Coutinho W. A randomized, double-blind, placebo-controlled study of sibutramine in the treatment of binge-eating disorder. Arch Gen Psychiatry. 2003;60(11):1109–16.CrossRefPubMedGoogle Scholar
  18. 18.
    Burgmer R, Grigutsch K, Zipfel S, Wolf AM, de Zwaan M, Husemann B, Albus C, Senf W, Herpertz S. The influence of eating behavior and eating pathology on weight loss after gastric restriction operations. Obes Surg. 2005;15(5):684–91.CrossRefPubMedGoogle Scholar
  19. 19.
    O’Reardon JP, Stunkard AJ, Allison KC. Clinical trial of sertraline in the treatment of night eating syndrome. Int J Eat Disord. 2004;35(1):16–26.CrossRefPubMedGoogle Scholar
  20. 20.
    O’Reardon JP, Allison KC, Martino NS, Lundgren JD, Heo M, Stunkard AJ. A randomized, placebo-controlled trial of sertraline in the treatment of night eating syndrome. Am J Psychiatry. 2006;163(5):893–8.CrossRefPubMedGoogle Scholar
  21. 21.
    Powers PS, Perez A, Boyd F, Rosemurgy A. Eating pathology before and after bariatric surgery: a prospective study. Int J Eat Disord. 1999;25(3):293–300.CrossRefPubMedGoogle Scholar
  22. 22.
    American College of Sports Medicine. Appropriate physical activity intervention strategies for weight loss and prevention of weight regain for adults. Med Sci Sports Exerc. 2009;43:459–71.Google Scholar
  23. 23.
    Sacks FM, Bray GA, Carey VJ, Smith SR, Ryan DH, et al. Comparison of weight-loss diets with different compositions of fat, protein, and carbohydrates. N Engl J Med. 2009;360:859–73.PubMedCentralCrossRefPubMedGoogle Scholar
  24. 24.
    Keogh JB, Clifton PM. The role of meal replacements in obesity treatment. Obes Rev. 2005;26:229–34.CrossRefGoogle Scholar
  25. 25.
    Rock CL, Flatt SW, Sherwood NE, Karanja N, Pakiz B, et al. Effect of a free prepared meal and incentivized weight loss program on weight loss and weight loss maintenance in obese and overweight women. A randomized trial. JAMA. 2010;304:1803–11.CrossRefPubMedGoogle Scholar
  26. 26.
    Jebb SA, Ahern AL, Olson AD, Aston LM, Holzapfel C, et al. Primary care referral to a commercial provider for weight loss treatment versus standard care: a randomized controlled trial. Lancet. 2011;378:1485–92.PubMedCentralCrossRefPubMedGoogle Scholar
  27. 27.
    American College of Sports Medicine. ACSM’s guidelines for exercise testing and prescription. 7th ed. Philadelphia: Lippicott Williams & Wilkins, Publ; 2006.Google Scholar
  28. 28.
    2008 Physical Activity Guidelines for Americans. U. S. Department of Health and Human Services; 2008. www.health.gov/paguidelines.
  29. 29.
    Burke LE, Wang J, Sevick MA. Self-monitoring in weight loss: a systematic review of the literature. J Am Diet Assoc. 2011;111:92–102.PubMedCentralCrossRefPubMedGoogle Scholar
  30. 30.
    Franz MJ, VanWormer JJ, Crain AL, Boucher JL, Histon T, Caplan W, Bowman JD, Pronk NP. Weight-loss outcomes: a systematic review and meta-analysis of weight-loss clinical trials with a minimum 1-year follow-up. J Am Diet Assoc. 2007;107(10):1755–6.CrossRefPubMedGoogle Scholar
  31. 31.
    O’Meara S, Riemsma R, Shirran L, Mather L, ter Riet G. A systematic review of the clinical effectiveness of orlistat used for the management of obesity. Obes Rev. 2004;5:51–68.CrossRefPubMedGoogle Scholar
  32. 32.
    Padwal RS, Majumdar SR. Drug treatments for obesity: orlistat, sibutramine, and rimonabant. Lancet. 2007;369:71–7.CrossRefPubMedGoogle Scholar
  33. 33.
    Rucker D, Padwal R, Li SK, Curioni C, Lau DC. Long term pharmacotherapy for obesity and overweight: updated meta-analysis. BMJ. 2007;335:1194–9.PubMedCentralCrossRefPubMedGoogle Scholar
  34. 34.
    Smith SR, Weissman NJ, Anderson CM, Sanchez M, Chuang E, et al. Multicenter, placebo-controlled trial of lorcaserin for weight management. N Engl J Med. 2010;363:245–56.CrossRefPubMedGoogle Scholar
  35. 35.
    Fidler MC, Sanchez M, Raether B, Weissman NJ, Smith SR, et al. A one-year randomized trial of lorcaserin for weight loss in obese and overweight adults: the BLOSSOM trial. J Clin Endocrinol Metab. 2011;96:3067–77.CrossRefPubMedGoogle Scholar
  36. 36.
    Allison DB, Gadde KM, Garvey WT, Peterson CA, Schwiers ML, et al. Controlled-release phentermine/topiramate in severely obese adults: a randomized controlled trial (EQUIP). Obesity. 2012;20(2):330–42.PubMedCentralCrossRefPubMedGoogle Scholar
  37. 37.
    Gadde KM, Allison DB, Ryan DH, Peterson CA, Troupin B, et al. Effects of low-dose, controlled-release, phentermine plus topiramate combination on weight and associated comorbidities in overweight and obese adults (CONQUER): a randomized, placebo-controlled, phase 3 trial. Lancet. 2011;377:1341–52.CrossRefPubMedGoogle Scholar
  38. 38.
    National Institute for Clinical Excellence. National Institute for Clinical Excellence GC43 obesity: NICE guideline. 2006. Http://www.nice.org.uk/guidance/cg43/resources/guidance-obesity-pdf.
  39. 39.
    Mechanick JI, Youdim A, Jones DB, Timothy Garvey W, Hurley DL, et al. Clinical practice guidelines for the perioperative nutritional, metabolic, and nonsurgical support of the bariatric surgery patient—2013 update: cosponsored by American Association of Clinical Endocrinologists, the Obesity Society, and American Society for Metabolic & Bariatric Surgery. Surg Obes Relat Dis. 2013;9(2):159–91.CrossRefPubMedGoogle Scholar

Copyright information

© Springer International Publishing Switzerland 2016

Authors and Affiliations

  1. 1.Department School of Clinical Sciences, School of Clinical SciencesUniversity of Bristol, Southmead HospitalBristolUK

Personalised recommendations